Jon Faldasz: Ondansetron May Have Cardiotoxicity Risk Among 5-HT3RAs Due to High Concentration in Cardiac Tissues
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Just dropped: Ondansetron may have outstanding cardiotoxicity risk among 5-HT3RAs due to high concentration in cardiac tissues
Published today in Nature Scientific Reports, Cai et al used the FDA’s Adverse Event Reporting System (FAERS) to review records of cardiotoxicity associated with 5-HT3RA use. They found:
– The different 5-HT3RAs exhibit varying degrees and types of cardiotoxicity
– QT prolongation was most common for ondansetron (granisetron was least common)
– In a subsequent PBPK model extrapolation they estimated that ondansetron concentrations in cardiac tissue were 2.3x higher than plasma.
They suggested that providers might “prioritize low cardiac toxicity 5-HT3RAs” (read: avoid ondansetron) in patients with heart disease.
For my part, FAERS seems like an untapped resource for this type of work, now I’m thinking on what other investigations could make use of it.
Article reference here.”
Title: Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study
Authors: Yijun Cai, Shaohong Luo, Shen Lin, Xiaoting Huang, Xiangzhen Wang, Lijing Yang, Xiongwei Xu, Xiuhua Weng

Stay updated with Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke